Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Samarium-153-EDTMP biodistribution and dosimetry estimation

J F Eary1, C Collins, M Stabin

  • 1Department of Radiology, University of Washington Medical Center, Seattle 98195.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In situ formation of micro/nano phase composite for 3D printing clinically relevant bioresorbable stents.

Materials today. Chemistry·2025
Same author

Features and frequency of use of electronic health records in primary care across 20 countries: a cross-sectional study.

Public health·2024
Same author

Extending Pharmacy Services to the Point of Discharge.

Irish medical journal·2023
Same author

Recurrent Lung Injury Resulting From Unusual Cases of Aero-Digestive Disease.

Dysphagia·2023
Same author

Characteristics and outcomes of hospitalised inpatients with indwelling urinary catheter-a retrospective study from a large regional hospital in Queensland.

Infection, disease & health·2022
Same author

Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report.

Journal of medical case reports·2022

Samarium-153 (153Sm) EDTMP effectively palliates bone pain in metastatic prostate cancer. This Phase I trial demonstrated rapid bone uptake and clearance of 153Sm-EDTMP, indicating good tolerability and potential for therapeutic use.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmacology

Background:

  • Metastatic prostate carcinoma frequently causes debilitating bone pain.
  • Effective pain palliation is crucial for improving patient quality of life.
  • Radiopharmaceuticals offer targeted therapy for bone metastases.

Purpose of the Study:

  • To evaluate the safety and toxicity of single doses of Samarium-153 ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) in patients with prostate cancer bone pain.
  • To assess the biodistribution and dosimetry of 153Sm-EDTMP.
  • To establish an escalating dose protocol for potential therapeutic applications.

Main Methods:

  • Phase I clinical trial involving 52 patients with metastatic prostate carcinoma.
  • Administration of single escalating doses of 153Sm-EDTMP (1.0 to 3.0 mCi/kg).

Related Experiment Videos

  • Pre- and post-treatment screening and 99mTc-MDP bone scans for monitoring.
  • Biodistribution data acquisition and dosimetry estimations.

    • Main Results:

    • Rapid uptake of 153Sm-EDTMP into bone was observed.
    • Complete clearance of non-skeletal radioactivity within 6-8 hours.
    • Estimated radiation absorbed doses: ~25,000 mrad/mCi to bone surfaces and ~3600 mrad/mCi to the urinary bladder.
    • No specific toxicity data mentioned, but the dose escalation implies safety evaluation.

    Conclusions:

    • 153Sm-EDTMP shows favorable biodistribution characteristics for bone palliation.
    • The radiopharmaceutical is rapidly cleared from non-target tissues.
    • Dosimetry suggests a potential therapeutic window for managing bone pain in prostate cancer.